Drug Profile
Research programme: synthetic macrocycles - Ensemble Therapeutics/Alexion AstraZeneca Rare Disease
Latest Information Update: 29 Jul 2021
Price :
$50
*
At a glance
- Originator Alexion Pharmaceuticals; Ensemble Therapeutics
- Developer Alexion AstraZeneca Rare Disease; Ensemble Therapeutics
- Class Macrocyclic compounds; Small molecules
- Mechanism of Action Protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 21 Jul 2021 Alexion Pharmaceuticals has been acquired by AstraZeneca and changed its name to Alexion AstraZeneca Rare Disease
- 04 Nov 2017 No recent reports of development identified for research development in Undefined in USA
- 18 Jul 2013 Early research in Undefined indication in USA (unspecified route)